SIGLEC12 expression was found to be upregulated in bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma (CESC), esophageal earcinoma (ESCA), and Glioblastoma multiforme tumours (GBM) when compared to the normal sample type (Fig. 2). This evidence concerns the gene SIGLEC12 and bladder transitional cell carcinoma.